Display options
Cite
Badura-Stronka M, Hirschfeld AS, Winczewska-Wiktor A, et al. First case series of Polish patients with cerebrotendinous xanthomatosis and systematic review of cases from the 21st century. Clin Genet. 2021;101(2):190-207doi: 10.1111/cge.14079.
Badura-Stronka, M., Hirschfeld, A. S., Winczewska-Wiktor, A., Budzyńska, E., Jakubiuk-Tomaszuk, A., Piontek, A., Steinborn, B., & Kozubski, W. (2022). First case series of Polish patients with cerebrotendinous xanthomatosis and systematic review of cases from the 21st century. Clinical genetics, 101(2), 190-207. https://doi.org/10.1111/cge.14079
Badura-Stronka, Magdalena, et al. "First case series of Polish patients with cerebrotendinous xanthomatosis and systematic review of cases from the 21st century." Clinical genetics vol. 101,2 (2022): 190-207. doi: https://doi.org/10.1111/cge.14079
Badura-Stronka M, Hirschfeld AS, Winczewska-Wiktor A, Budzyńska E, Jakubiuk-Tomaszuk A, Piontek A, Steinborn B, Kozubski W. First case series of Polish patients with cerebrotendinous xanthomatosis and systematic review of cases from the 21st century. Clin Genet. 2022 Feb;101(2):190-207. doi: 10.1111/cge.14079. Epub 2021 Nov 24. PMID: 34689324.
Copy Download .nbib Format: NLM
Share it on

Clin Genet. 2022 Feb;101(2):190-207. doi: 10.1111/cge.14079. Epub 2021 Nov 24.

First case series of Polish patients with cerebrotendinous xanthomatosis and systematic review of cases from the 21st century.

Clinical genetics

Magdalena Badura-Stronka, Adam Sebastian Hirschfeld, Anna Winczewska-Wiktor, Edyta Budzyńska, Anna Jakubiuk-Tomaszuk, Anita Piontek, Barbara Steinborn, Wojciech Kozubski

Affiliations

  1. Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland.
  2. Centers for Medical Genetics GENESIS, Poznan, Poland.
  3. Department of Child Neurology, Poznan University of Medical Sciences, Poznan, Poland.
  4. Central Teaching Hospital, The Medical University of Lodz, Poland.
  5. Department of Pediatric Neurology and Rehabilitation, Medical University of Bialystok, Poland.
  6. Medical Genetics Unit, Mastermed Medical Center, Poland.
  7. Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.

PMID: 34689324 DOI: 10.1111/cge.14079

Abstract

Cerebrotendinous xanthomatosis (CTX) is an inborn error of metabolism caused by recessive variants in the cytochrome P450 CYP27A1 gene. CTX is said to manifest with childhood-onset chronic diarrhea and the classic triad of juvenile-onset cataracts, Achilles tendons xanthomas, and progressive ataxia. It is currently one of the few inherited neurometabolic disorders amenable to a specific treatment. The diagnosis may be significantly delayed resulting in permanent neurological impairment. A retrospective review of the clinical characteristics and diagnostic findings in case series of six Polish patients with CTX. Additional retrospective review of symptoms and pathogenic variants of 568 CTX available cases and case series from the past 20 years. To the best of our knowledge, this is the widest review of CTX cases reported in years 2000-2021. We report the largest cohort of Polish patients ever published, with the identification of two hot-spot mutations. During the review of available 568 cases, we found significant differences in the clinical phenotypes and the localization of variants within the gene between Asian and non-Asian populations. These findings may facilitate molecular testing in the Polish and Asian populations. Invariably better screening for CTX and wider awareness is needed.

© 2021 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.

Keywords: CTX; CYP27A1; Polish; cerebrotendinous xanthomatosis; hot-spot

References

  1. Van Bogaert L, Scherer HJ, Epstein E. Une Forme Cerebrale De La Cholesterinose Generalisee. Masson; 1937:1-159. - PubMed
  2. Epstein E, Lorenz K. Beitrag zur Pathologie und Pathochemie der Cholesterinigen Lipoidose vom Typus Bogaert-Scherer. Klin Wochenschr. 1937;16:1320-1323. doi:10.1007/BF01777165 - PubMed
  3. Philippart M, Van Bogaert L. Cholestanolosis (cerebrotendinous xanthomatosis). A follow-up study on the original family. Arch Neurol. 1969;21(6):603-610. doi:10.1001/archneur.1969.00480180059004 - PubMed
  4. Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266(12):7779-7783. - PubMed
  5. Stelten BML, Huidekoper HH, van de Warrenburg BPC, et al. Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology. 2019;92(2):e83-e95. doi:10.1212/WNL.0000000000006731 - PubMed
  6. Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18(10):1203-1211. doi:10.1111/j.1468-1331.2011.03439.x - PubMed
  7. Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis. 2017;40(6):771-781. doi:10.1007/s10545-017-0093-8 - PubMed
  8. Tao QQ, Zhang Y, Lin HX, Dong HL, Ni W, Wu ZY. Clinical and genetic characteristics of Chinese patients with cerebrotendinous xanthomatosis. Orphanet J Rare Dis. 2019;14(1):282. doi:10.1186/s13023-019-1252-9 - PubMed
  9. Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol. 2005;62(9):1459-1463. doi:10.1001/archneur.62.9.1459 - PubMed
  10. Raymond GV, Schiffmann R. Cerebrotendinous xanthomatosis: the rare “treatable” disease you never consider. Neurology. 2019;92(2):61-62. doi:10.1212/WNL.0000000000006721 - PubMed
  11. Cao LX, Yang M, Liu Y, Long WY, Zhao GH. Chinese patient with cerebrotendinous xanthomatosis confirmed by genetic testing: a case report and literature review. World J Clin Cases. 2020;8(21):5446-5456. doi:10.12998/wjcc.v8.i21.5446 - PubMed
  12. Salen G, Meriwether TW, Nicolau G. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med. 1975;14(1):57-74. doi:10.1016/0006-2944(75)90020-4 - PubMed
  13. Yunisova G, Tufekcioglu Z, Dogu O, et al. Patients with lately diagnosed cerebrotendinous xanthomatosis. Neurodegener Dis. 2019;19(5-6):218-224. doi:10.1159/000506770 - PubMed
  14. Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain. 2000;123(5):908-919. doi:10.1093/brain/123.5.908 - PubMed
  15. Koyama S, Sekijima Y, Ogura M, et al. Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical Spectrum, diagnosis, and disease-modifying treatments. J Atheroscler Thromb. 2021;28:905-925. doi:10.5551/jat.RV17055 - PubMed
  16. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. doi:10.1136/bmj.g7647 - PubMed
  17. Ostrowska M, Banaszkiewicz K, Kiławiec A, Róg T, Lütjohann D, Szczudlik A. Cerebrotendinous xanthomatosis: a rare cause of spinocerebellar syndrome. Neurol Neurochir pol. 2011;45(6):600-603. doi:10.1016/S0028-3843(14)60128-6 - PubMed
  18. Lipiński P, Klaudel-Dreszler M, Ciara E, et al. Sterol 27-hydroxylase deficiency as a cause of neonatal cholestasis: report of 2 cases and review of the literature. Front Pediatr. 2021;8:616582. doi:10.3389/fped.2020.616582 - PubMed
  19. Duell PB, Salen G, Eichler FS, et al. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol. 2018;12(5):1169-1178. doi:10.1016/j.jacl.2018.06.008 - PubMed
  20. Kısa PT, Yildirim GK, Hismi BO, et al. Patients with cerebrotendinous xanthomatosis diagnosed with diverse multisystem involvement. Metab Brain Dis. 2021;36:1201-1211. doi:10.1007/s11011-021-00714-7 - PubMed
  21. Zubarioglu T, Kiykim E, Yesil G, et al. Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey. Acta Neurol Belg. 2019;119(3):343-350. doi:10.1007/s13760-017-0851-2 - PubMed
  22. Gallus GN, Dotti MT, Mignarri A, et al. Four novel CYP27A1 mutations in seven Italian patients with CTX. Eur J Neurol. 2010;17(10):1259-1262. doi:10.1111/j.1468-1331.2010.03002.x - PubMed
  23. Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics. 2009;123(1):143-147. doi:10.1542/peds.2008-0192 - PubMed
  24. Degos B, Nadjar Y, Amador Mdel M, et al. Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. Orphanet J Rare Dis. 2016;11:41. doi:10.1186/s13023-016-0419-x - PubMed
  25. Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013;36(3):78-83. doi:10.1097/WNF.0b013e318288076a - PubMed
  26. Grandas F, Martín-Moro M, Garcia-Muñozguren S, Anaya F. Early-onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord. 2002;17(6):1396-1397. doi:10.1002/mds.10287 - PubMed
  27. Jiang J, Chen G, Wu J, et al. c.1263+1G>A is a latent hotspot for CYP27A1 mutations in Chinese patients with cerebrotendinous xanthomatosis. Front Genet. 2020;11:682. doi:10.3389/fgene.2020.00682 - PubMed
  28. Mignarri A, Dotti MT, Federico A, et al. The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J Neurol. 2017;264(5):862-874. doi:10.1007/s00415-017-8440-0 - PubMed
  29. Stelten BML, Raal FJ, Marais AD, et al. Cerebrotendinous xanthomatosis without neurological involvement. J Intern Med. 2021;290:1039-1047. doi:10.1111/joim.13277 - PubMed
  30. Guenzel AJ, DeBarber A, Raymond K, Dhamija R. Familial variability of cerebrotendinous xanthomatosis lacking typical biochemical findings. JIMD Rep. 2021;59(1):3-9. doi:10.1002/jmd2.12197 - PubMed
  31. Parry AH, Wani AH, Bashir M, Gojwari TA. Cerebrotendinous xanthomatosis-a case report. Indian J Radiol Imaging. 2019;29(3):332-334. doi:10.4103/ijri.IJRI_444_18 - PubMed
  32. Ma C, Ren YD, Wang JC, et al. The clinical and imaging features of cerebrotendinous xanthomatosis: a case report and review of the literature. Medicine (Baltimore). 2021;100(9):e24687. doi:10.1097/MD.0000000000024687 - PubMed
  33. Zhang Y, Sun YM, Li H. Teaching neuroimages: symmetric deep cerebellar white matter T2 and SWI hypointense lesions in a case of cerebrotendinous xanthomatosis. Neurology. 2021;97:e968-e969. doi:10.1212/WNL.0000000000012154 - PubMed
  34. Atallah I, Millán DS, Benoît W, Campos-Xavier B, Superti-Furga A, Tran C. Spinal cerebrotendinous xanthomatosis: a case report and literature review. Mol Genet Metab Rep. 2021;26:100719. doi:10.1016/j.ymgmr.2021.100719 - PubMed
  35. Degrassi I, Amoruso C, Giordano G, et al. Case report: early treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis presenting as neonatal cholestasis. Front Pediatr. 2020;8:382. doi:10.3389/fped.2020.00382 - PubMed
  36. Baghbanian SM, Mahdavi Amiri MR, Majidi H. Cerebrotendinous xanthomatosis revisited. Pract Neurol. 2021;21(3):243-245. doi:10.1136/practneurol-2020-002895 - PubMed
  37. Wong JC, Walsh K, Hayden D, Eichler FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41(4):647-656. doi:10.1007/s10545-018-0152-9 - PubMed
  38. Islam M, Hoggard N, Hadjivassiliou M. Cerebrotendinous Xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid. Cerebellum Ataxias. 2021;8(1):5. doi:10.1186/s40673-021-00128-2 - PubMed
  39. Zhang T, Yan C, Liu Y, et al. Late-onset leukodystrophy mimicking hereditary spastic paraplegia without diffuse leukodystrophy on neuroimaging. Neuropsychiatr Dis Treat. 2021;17:1451-1458. doi:10.2147/NDT.S296424 - PubMed
  40. Takasone K, Morizumi T, Nakamura K, et al. A late-onset and relatively rapidly progressive case of pure spinal form cerebrotendinous xanthomatosis with a novel mutation in the CYP27A1 gene. Intern Med. 2020;59(20):2587-2591. doi:10.2169/internalmedicine.5037-20 - PubMed
  41. Mandrile G, Gallus GN, Mura G, et al. Cerebrotendinous xanthomatosis: recurrence of the CYP27A1 mutation p.Arg479Cys in Sardinia. Neurol Sci. 2014;35(8):1303-1305. doi:10.1007/s10072-014-1696-6 - PubMed
  42. Mutlu D, Tuncer A, Gocmen R, Yalcin-Cakmakli G, Saygı S, Elibol B. Diagnostic challenge: a case of late-onset spinal form cerebrotendinous xanthomatosis. Neurology. 2019;92(9):438-439. doi:10.1212/WNL.0000000000007015 - PubMed
  43. Koyama S, Kawanami T, Tanji H, et al. A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosurg. 2012;114(7):1021-1023. doi:10.1016/j.clineuro.2012.01.032 - PubMed
  44. Yoshinaga T, Sekijima Y, Koyama S, et al. Clinical and radiological findings of a cerebrotendinous xanthomatosis patient with a novel p.A335V mutation in the CYP27A1 gene. Intern Med. 2014;53(23):2725-2729. doi:10.2169/internalmedicine.53.2996 - PubMed
  45. Sasamura A, Akazawa S, Haraguchi A, et al. Late-onset cerebrotendinous xanthomatosis with a novel mutation in the CYP27A1 gene. Intern Med. 2018;57(11):1611-1616. doi:10.2169/internalmedicine.0120-17 - PubMed
  46. Alhariri A, Hamilton K, Oza V, et al. Clinical report: a patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment. Am J Med Genet A. 2017;173(8):2275-2279. doi:10.1002/ajmg.a.38314 - PubMed
  47. Suh S, Kim HK, Park HD, et al. Three siblings with Cerebrotendinous Xanthomatosis: a novel mutation in the CYP27A1 gene. Eur J Med Genet. 2012;55(1):71-74. doi:10.1016/j.ejmg.2011.08.003 - PubMed
  48. Weissfeld T, Ratliff J. Cerebrotendinous xanthomatosis ataxia responsive to CDCA and Riluzole. J Clin Neurosci. 2018;53:263-264. doi:10.1016/j.jocn.2018.04.043 - PubMed
  49. Catarino CB, Vollmar C, Küpper C, et al. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment. J Neurol. 2018;265(2):388-393. doi:10.1007/s00415-017-8711-9 - PubMed
  50. Rosafio F, Cavallieri F, Guaraldi P, Taroni F, Nichelli PF, Mandrioli J. The wide spectrum of cerebrotendinous xanthomatosis: case report of a rare but treatable disease. Clin Neurol Neurosurg. 2016;143:1-3. doi:10.1016/j.clineuro.2016.01.032 - PubMed
  51. Yanagihashi M, Kano O, Terashima T, et al. Late-onset spinal form xanthomatosis without brain lesion: a case report. BMC Neurol. 2016;16:21. doi:10.1186/s12883-016-0542-2 - PubMed
  52. Szlago M, Gallus GN, Schenone A, et al. The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Neurology. 2008;70(5):402-404. doi:10.1212/01.wnl.0000280460.28039.3d - PubMed
  53. Saute JA, Giugliani R, Merkens LS, Chiang JP, DeBarber AE, de Souza CF. Look carefully to the heels! A potentially treatable cause of spastic paraplegia. J Inherit Metab Dis. 2015;38(2):363-364. doi:10.1007/s10545-014-9745-0 - PubMed
  54. Varman KM, Dunbar K, Usifo K, Stevens CA. Cerebrotendinous xanthomatosis: a treatable genetic disease not to be missed. J Clin Rheumatol. 2016;22(2):92-93. doi:10.1097/RHU.0000000000000367 - PubMed
  55. Sekijima Y, Koyama S, Yoshinaga T, Koinuma M, Inaba Y. Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet. 2018;63(3):271-280. doi:10.1038/s10038-017-0389-4 - PubMed
  56. Nozue T, Higashikata T, Inazu A, et al. Identification of a novel missense mutation in the sterol 27-hydroxylase gene in two Japanese patients with cerebrotendinous xanthomatosis. Intern Med. 2010;49(12):1127-1131. doi:10.2169/internalmedicine.49.3277 - PubMed
  57. Lee CW, Lee JJ, Lee YF, et al. Clinical and molecular genetic features of cerebrotendinous xanthomatosis in Taiwan: report of a novel CYP27A1 mutation and literature review. J Clin Lipidol. 2019;13(6):954-9.e1. doi:10.1016/j.jacl.2019.10.001 - PubMed
  58. Wallon D, Guyant-Maréchal L, Laquerrière A, et al. Clinical imaging and neuropathological correlations in an unusual case of cerebrotendinous xanthomatosis. Clin Neuropathol. 2010;29(6):361-364. doi:10.5414/npp29361 - PubMed
  59. Luyckx E, Eyskens F, Simons A, Beckx K, Van West D, Dhar M. Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. Clin Neurol Neurosurg. 2014;118:9-11. doi:10.1016/j.clineuro.2013.12.008 - PubMed
  60. Kapás I, Katkó M, Harangi M, et al. Cerebrotendinous xanthomatosis with the c.379C>T (p.R127W) mutation in the CYP27A1 gene associated with premature age-associated limbic tauopathy. Neuropathol Appl Neurobiol. 2014;40(3):345-350. doi:10.1111/nan.12058 - PubMed
  61. Di Taranto MD, Gelzo M, Giacobbe C, et al. Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports. Metab Brain Dis. 2016;31(5):1185-1188. doi:10.1007/s11011-016-9841-y - PubMed
  62. Gonzalez-Cuyar LF, Hunter B, Harris PL, Perry G, Smith MA, Castellani RJ. Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Rep. 2007;12(3):119-124. doi:10.1179/135100007X200173 - PubMed
  63. Lange MC, Zétola VF, Teive HA, et al. Cerebrotendinous xanthomatosis: report of two Brazilian brothers. Arq Neuropsiquiatr. 2004;62(4):1085-1089. doi:10.1590/s0004-282x2004000600028 - PubMed
  64. Schneider H, Lingesleben A, Vogel HP, Garuti R, Calandra S. A novel mutation in the sterol 27-hydroxylase gene of a woman with autosomal recessive cerebrotendinous xanthomatosis. Orphanet J Rare Dis. 2010;5:27. doi:10.1186/1750-1172-5-27 - PubMed
  65. Lee MJ, Huang YC, Sweeney MG, Wood NW, Reilly MM, Yip PK. Mutation of the sterol 27-hydroxylase gene ( CYP27A1) in a Taiwanese family with cerebrotendinous xanthomatosis. J Neurol. 2002;249(9):1311-1312. doi:10.1007/s00415-002-0762-9 - PubMed
  66. Chen WC, Wu KC, Hu CH, Chern TC, Jou IM. A compound heterozygous mutation of CYP27A1 gene in a Taiwanese patient with cerebrotendinous xanthomatosis. J Orthop Sci. 2011;16(6):825-827. doi:10.1007/s00776-011-0072-0 - PubMed
  67. Monson DM, DeBarber AE, Bock CJ, et al. Cerebrotendinous xanthomatosis: a treatable disease with juvenile cataracts as a presenting sign. Arch Ophthalmol. 2011;129(8):1087-1088. doi:10.1001/archophthalmol.2011.219 - PubMed
  68. Desai KM, Kumar P, Ravat PS, et al. Progressive myoclonic epilepsy'-like presentation of cerebrotendinous xanthomatosis in an Indian family with A novel C.646+1G>A splice site mutation. Epilepsy Behav Rep. 2020;15:100401. doi:10.1016/j.ebr.2020.100401 - PubMed
  69. Abe R, Sekijima Y, Kinoshita T, et al. Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion. J Spinal Cord Med. 2016;39(6):726-729. doi:10.1179/1079026815Z.000000000409 - PubMed
  70. Chen C, Zhang Y, Wu H, et al. Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families. Metab Brain Dis. 2017;32(5):1609-1618. doi:10.1007/s11011-017-0047-8 - PubMed
  71. Gelzo M, Di Taranto MD, Bisecco A, et al. A case of cerebrotendinous xanthomatosis with spinal cord involvement and without tendon xanthomas: identification of a new mutation of the CYP27A1 gene. Acta Neurol Belg. 2021;121(2):561-566. doi:10.1007/s13760-019-01267-4 - PubMed
  72. Bryant AM, Block C. A neuropsychological profile for cerebrotendinous xanthomatosis: a single-case study. J Int Neuropsychol Soc. 2020;26(4):441-449. doi:10.1017/S1355617719001292 - PubMed
  73. Mignarri A, Magni A, Del Puppo M, et al. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2016;39(1):75-83. doi:10.1007/s10545-015-9873-1 - PubMed
  74. Roeben B, Just J, Hengel H, et al. Multifocal, hypoechogenic nerve thickening in cerebrotendinous xanthomatosis. Clin Neurophysiol. 2020;131(8):1798-1803. doi:10.1016/j.clinph.2020.04.162 - PubMed
  75. Seidel S, Kasprian G, Prayer D, Krssák M, Sycha T, Auff E. Visualisation of treatment response in a case of cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry. 2011;82(6):703-704. doi:10.1136/jnnp.2009.196444 - PubMed
  76. Ginanneschi F, Mignarri A, Mondelli M, Gallus GN, Del Puppo M, Giorgi S. Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol. 2013;260(1):268-274. doi:10.1007/s00415-012-6630-3 - PubMed
  77. Saussy K, Jain N, Murina A. Cerebrotendinous xanthomatosis: a report of 3 cases. JAAD Case Rep. 2020;6(12):1205-1207. doi:10.1016/j.jdcr.2020.10.012 - PubMed
  78. Mukaino A, Tsuda M, Yamashita S, Kosaka T, Wada K, Ando Y. Cerebrotendinous xanthomatosis presenting with extensive cerebral cortex symptoms: a case report. Clin Neurol Neurosurg. 2018;174:217-219. doi:10.1016/j.clineuro.2018.09.028 - PubMed
  79. Tang Y, Liu Y, Li D, Guo D, Xing Y. A novel mutation in the CYP27A1 gene in a family with cerebrotendinous xanthomatosis. Int J Neurosci. 2020;130(10):972-975. doi:10.1080/00207454.2020.1713774 - PubMed
  80. Zhang S, Li W, Zheng R, et al. Cerebrotendinous xanthomatosis with peripheral neuropathy: a clinical and neurophysiological study in Chinese population. Ann Transl Med. 2020;8(21):1372. doi:10.21037/atm-20-2746 - PubMed
  81. Gong JY, Setchell KDR, Zhao J, et al. Severe neonatal cholestasis in cerebrotendinous xanthomatosis: genetics, immunostaining, mass spectrometry. J Pediatr Gastroenterol Nutr. 2017;65(5):561-568. doi:10.1097/MPG.0000000000001730 - PubMed
  82. Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis. 2008;31(2):S241-S245. doi:10.1007/s10545-008-0815-z - PubMed
  83. Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2002;25(6):501-513. doi:10.1023/a:1021211520034 - PubMed
  84. Tada H, Inaba S, Pozharitckaia D, Kawashiri MA. Prominent tendon xanthomas and abdominal aortic aneurysm associated with cerebrotendinous xanthomatosis identified using whole exome sequencing. Intern Med. 2018;57(8):1119-1122. doi:10.2169/internalmedicine.9687-17 - PubMed
  85. Li J, Xu EH, Mao W, et al. Parkinsonism with normal dopaminergic presynaptic terminals in cerebrotendinous xanthomatosis. Mov Disord Clin Pract. 2019;7(1):115-116. doi:10.1002/mdc3.12846 - PubMed
  86. Miyamoto M, Ishii N, Mochizuki H, et al. Optic neuropathy with features suggestive of optic neuritis in cerebrotendinous xanthomatosis. Case Rep Neurol Med. 2019;2019:2576826. doi:10.1155/2019/2576826 - PubMed
  87. Chang CC, Lui CC, Wang JJ, et al. Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurol. 2010;10:59. doi:10.1186/1471-2377-10-59 - PubMed
  88. Chen Q, Liu W, Jiang B, Yu R, Li X, Li H. Fluoxetine-responsive depression in a Chinese cerebrotendinous xanthomatosis. Gen Hosp Psychiatry. 2012;34(5):578.e1-578.e4. doi:10.1016/j.genhosppsych.2011.10.008 - PubMed
  89. Ito S, Kuwabara S, Sakakibara R, et al. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci. 2003;216(1):179-182. doi:10.1016/j.jns.2003.07.005 - PubMed
  90. Lee Y, Lin PY, Chiu NM, Chang WN, Wen JK. Cerebrotendinous xanthomatosis with psychiatric disorders: report of three siblings and literature review. Chang Gung Med J. 2002;25(5):334-340. - PubMed
  91. Hashimoto T, Sennari Y, Okada K, Adachi H. Cerebrotendinous xanthomatosis with nodular-hypertrophy of the lumbosacral roots. Intern Med. 2018;57(11):1669-1670. doi:10.2169/internalmedicine.9883-17 - PubMed
  92. Wang Z, Yuan Y, Zhang W, Zhang Y, Feng L. Cerebrotendinous xanthomatosis with a compound heterozygote mutation and severe polyneuropathy. Neuropathology. 2007;27(1):62-66. doi:10.1111/j.1440-1789.2006.00739.x - PubMed
  93. Tian D, Zhang ZQ. 2 Novel deletions of the sterol 27-hydroxylase gene in a Chinese family with cerebrotendinous xanthomatosis. BMC Neurol. 2011;11:130. doi:10.1186/1471-2377-11-130 - PubMed
  94. Qian Q, Cao D, Wei YD. A rare form of lipid metabolic encephalopathy. JAMA Neurol. 2020;77(1):131-132. doi:10.1001/jamaneurol.2019.3551 - PubMed
  95. Toba H, Fukuyama R, Sasaki M, Shiga K, Ishibashi S, Fushiki S. A Japanese patient with cerebrotendinous xanthomatosis has different mutations within two functional domains of CYP27. Clin Genet. 2002;61(1):77-78. doi:10.1034/j.1399-0004.2002.610116.x - PubMed
  96. Parente F, Vesnaver M, Massie R, Baass A. An unusual cause of Achilles tendon xanthoma. J Clin Lipidol. 2016;10(4):1040-1044. doi:10.1016/j.jacl.2016.05.001 - PubMed
  97. Contreras JP, Guajardo G, Martínez A, López I, Cea G. Cerebrotendinous xanthomatosis. Report of one case. Rev Med Chil. 2019;147(5):658-662. doi:10.4067/S0034-98872019000500658 - PubMed
  98. Bhojwani RA, Khot R. Cerebrotendinous xanthomatosis: a rare genetic disorder. BMJ Case Rep. 2011;2011:bcr0820114582. doi:10.1136/bcr.08.2011.4582 - PubMed
  99. Kulkarni SD, Garg M, Sayed R. Cerebrotendinous xanthomatosis without skin changes: diagnostic delay and confirmation by genetic analysis. Indian Pediatr. 2016;53(10):917-919. doi:10.1007/s13312-016-0960-7 - PubMed
  100. Yoon JY, Kim MW, Do HJ, Jang DH, Lee HW. Sonographic findings of polyneuropathy associated with cerebrotendinous xanthomatosis: a case report. Ann Rehabil Med. 2001;41(2):313-317. doi:10.5535/arm.2017.41.2.313 - PubMed
  101. Bel S, García-Patos V, Rodríguez L, et al. Cerebrotendinous xanthomatosis. J Am Acad Dermatol. 2001;45(2):292-295. doi:10.1067/mjd.2001.113690 - PubMed
  102. Wejjakul W, Chatmaitri S, Wattanarojanaporn T, Pongkunakorn A, Ittiwut C, Shotelersuk V. Bilateral femoral neck fractures in cerebrotendinous xanthomatosis treated by hip arthroplasties: the first case report and literature review. J Orthop Case Rep. 2017;7(5):54-58. doi:10.13107/jocr.2250-0685.894 - PubMed
  103. Karakaplan M, Ergen E, Görmeli G, Korkmaz MF, Elmalı N. Bilateral Achilles tendon xanthomas in a patient with cerebrotendinous xanthomatosis A case report. J Am Podiatr Med Assoc. 2017;107(1):85-89. doi:10.7547/15-085 - PubMed
  104. Zádori D, Szpisjak L, Madar L, et al. Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series. Neurol Sci. 2017;38(3):481-483. doi:10.1007/s10072-016-2776-6 - PubMed
  105. Giraldo-Chica M, Acosta-Baena N, Urbano L, Velilla L, Lopera F, Pineda N. Novel cerebrotendinous xanthomatosis mutation causes familial early dementia in Colombia. Biomedica. 2015;35(4):563-571. doi:10.7705/biomedica.v35i4.2690 - PubMed
  106. Karandikar AA, Pushparajan S, Unni MN, Srinivas R. Case report: cerebrotendinous xanthomatosis. Indian J Radiol Imaging. 2009;19(4):314-317. doi:10.4103/0971-3026.57218 - PubMed
  107. Souto MJS, Almeida-Santos MA, Ferreira EJP, Gonçalves LFG, Oliveira JLM, Sousa ACS. Spontaneous coronary artery dissection in a patient with cerebrotendinous xanthomatosis. Arq Bras Cardiol. 2020;115(1):18-21. doi:10.36660/abc.20190456 - PubMed
  108. Kauffman MA, Gonzalez-Morón D, Consalvo D, Kochen S. Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. Am J Med Sci. 2012;343(4):332-333. doi:10.1097/MAJ.0b013e31823cf6d8 - PubMed
  109. Lagarde J, Roze E, Apartis E, et al. Myoclonus and dystonia in cerebrotendinous xanthomatosis. Mov Disord. 2012;27(14):1805-1810. doi:10.1002/mds.25206 - PubMed
  110. Saxena V, Pradhan P. Cerebrotendinous xanthomatosis; a genetic condition: clinical profile of three patients from a rural Indian family and review of literature. J Clin Orthop Trauma. 2016;7(2):122-126. doi:10.1016/j.jcot.2016.02.007 - PubMed
  111. Matysik S, Orsó E, Black A, Ahrens N, Schmitz G. Monitoring of 7α-hydroxy-4-cholesten-3-one during therapy of cerebrotendinous xanthomatosis: a case report. Chem Phys Lipids. 2011;164(6):530-534. doi:10.1016/j.chemphyslip.2011.05.001 - PubMed
  112. Mirzanli C, Esenyel CZ, Ozturk K, Baris A, Imren Y. Cerebrotendinous xanthomatosis presenting with bilateral Achilles tendon xanthomata: a case report. J Am Podiatr Med Assoc. 2013;103(2):152-155. doi:10.7547/1030152 - PubMed
  113. Shah K, Mathew V, Gallus GN, Dotti MT, Federico A, Danda S. Mutation analysis of cerebrotendinous xanthomatosis in an Indian case. Neurol India. 2012;60(6):643-644. doi:10.4103/0028-3886.105202 - PubMed
  114. Dutta AK, Danda S, Muthusamy K, et al. Cerebrotendinous xanthomatosis: possibility of founder mutation in CYP27A1 gene (c.526delG) in Eastern Indian and Surinamese population. Mol Genet Metab Rep. 2015;3:33-35. doi:10.1016/j.ymgmr.2015.03.002 - PubMed
  115. Tibrewal S, Duell PB, DeBarber AE, Loh AR. Cerebrotendinous xanthomatosis: early diagnosis on the basis of juvenile cataracts. J AAPOS. 2017;21(6):505-507. doi:10.1016/j.jaapos.2017.07.211 - PubMed
  116. Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A. Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol. 2008;255(6):839-842. doi:10.1007/s00415-008-0729-6 - PubMed
  117. Srinivas BH, Patnayak R, Rao IS, Prayaga A, Khan AK, Narasimhlu G. Cerebrotendinous xanthomatosis: a case report. Acta Cytol. 2007;51(4):654-656. doi:10.1159/000325820 - PubMed
  118. Castelnovo G, Jomir L, Bouly S. Cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry. 2003;74(9):1335. doi:10.1136/jnnp.74.9.1335 - PubMed
  119. Cerqueira AC, Nardi AE, Bezerra JM. Cerebrotendinous xanthomatosis: a treatable hereditary neuro-metabolic disease. Clinics (Sao Paulo). 2010;65(11):1217-1218. doi:10.1590/s1807-59322010001100028 - PubMed
  120. Guyant-Maréchal L, Verrips A, Girard C, et al. Unusual cerebrotendinous xanthomatosis with fronto-temporal dementia phenotype. Am J Med Genet A. 2005;139A(2):114-117. doi:10.1002/ajmg.a.30797 - PubMed
  121. Agrawal NK, Garg S. Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012;2012:bcr2012006202. doi:10.1136/bcr-2012-006202 - PubMed
  122. Jain RS, Sannegowda RB, Agrawal A, Hemrajani D, Jain R, Mathur T. “Hot cross bun” sign in a case of cerebrotendinous xanthomatosis: a rare neuroimaging observation. BMJ Case Rep. 2013;2013:bcr2012006641. doi:10.1136/bcr-2012-006641 - PubMed
  123. Dell'Aversano Orabona G, Dato C, Oliva M, et al. Multi-imaging study in a patient with cerebrotendinous xanthomatosis: radiology, clinic and pathology correlation of a rare condition. BJR Case Rep. 2020;6(1):20190047. doi:10.1259/bjrcr.20190047 - PubMed
  124. Okuma H, Kitagawa Y, Tokuoka K, Takagi S. Cerebrotendinous xanthomatosis with cerebellar ataxia as the chief symptom. Intern Med. 2007;46(15):1259-1261. doi:10.2169/internalmedicine.46.6448 - PubMed
  125. Migoya-Borja M, Cegla-Schvartzman F, Palomar-Ciria N, Iza M, Barrigón ML, Baca-García E. Clinical note: bipolar disorder in cerebrotendinous xanthomatosis: a case report. Actas Esp Psiquiatr. 2021;49(2):85-86. - PubMed
  126. Rystedt E, Olin M, Seyama Y, et al. Cerebrotendinous xanthomatosis: molecular characterization of two Scandinavian sisters. J Intern Med. 2002;252(3):259-264. doi:10.1046/j.1365-2796.2002.01033.x - PubMed
  127. Pudhiavan A, Agrawal A, Chaudhari S, Shukla A. Cerebrotendinous xanthomatosis-the spectrum of imaging findings. J Radiol Case Rep. 2013;7(4):1-9. doi:10.3941/jrcr.v7i4.1338 - PubMed
  128. Sastri V, Ravindranath VS, Metikala S, Kumar M. Bilateral Xanthomas of tendoachilles in a patient of cerebrotendinous xanthomatosis-a rare case report and review of literature. J Orthop Case Rep. 2014;4(4):40-43. doi:10.13107/jocr.2250-0685.223 - PubMed
  129. Kulkarni ML, Sreedhara MS, Kashinath SK, Kulkarni AM. Cerebrotendinous xanthomatosis: an early diagnosis by biochemical tests. Indian J Pediatr. 2014;81(8):840-841. doi:10.1007/s12098-013-1325-z - PubMed
  130. Lagarde J, Sedel F, Degos B. Blepharospasm as a new feature of cerebrotendinous xanthomatosis. Parkinsonism Relat Disord. 2013;19(8):764-765. doi:10.1016/j.parkreldis.2013.04.003 - PubMed
  131. Mignarri A, Falcini M, Vella A, et al. Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord. 2012;18(1):99-101. doi:10.1016/j.parkreldis.2011.06.004 - PubMed
  132. Nakamura S, Tamura T, Takahashi H, et al. Cerebrotendinous xanthomatosis: report of a case. Br J Dermatol. 2000;142(2):378-380. doi:10.1046/j.1365-2133.2000.03318.x - PubMed
  133. Rafiq M, Sharrack N, Shaw PJ, Hadjivassiliou M. A neurological rarity not to be missed: cerebrotendinous xanthomatosis. Pract Neurol. 2011;11(5):296-300. doi:10.1136/practneurol-2011-000003 - PubMed
  134. Smithard A, Lamyman MJ, McCarthy CL, Gibbons CL, Cooke PJ, Athanasou N. Cerebrotendinous xanthomatosis presenting with bilateral Achilles tendon xanthomata. Skeletal Radiol. 2007;36(2):171-175. doi:10.1007/s00256-006-0139-8 - PubMed
  135. Kottahachchi DC, Balasooriya BL, Panangala L, Ranawaka UK. Two siblings with cerebrotendinous xanthomatosis. Ceylon Med J. 2012;57(3):128-129. doi:10.4038/cmj.v57i3.4708 - PubMed
  136. Bartholdi D, Zumsteg D, Verrips A, et al. Spinal phenotype of cerebrotendinous xanthomatosis-a pitfall in the diagnosis of multiple sclerosis. J Neurol. 2004;251(1):105-107. doi:10.1007/s00415-004-0221-x - PubMed
  137. Brodsky JW, Beischer AD, Anat D, et al. Cerebrotendinous xanthomatosis: a rare cause of bilateral Achilles tendon swelling and ataxia. A case report. J Bone Joint Surg Am. 2006;88(6):1340-1344. doi:10.2106/JBJS.E.00872 - PubMed
  138. Burnett JR, Moses EA, Croft KD, et al. Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta. 2001;306(1-2):63-69. doi:10.1016/s0009-8981(01)00391-6 - PubMed
  139. Bajaj BK, Singh A, Anand KS, Garg J. Cerebrotendinous xanthomatosis: report of two cases and a novel genetic mutation in an Indian patient. J Neurosci Rural Pract. 2013;4(1):S87-S90. doi:10.4103/0976-3147.116420 - PubMed
  140. Fiebach JB. Cerebrotendinous xanthomatosis in a 12-year-old patient with growth disorder. Rofo. 2000;172(3):301-302. doi:10.1055/s-2000-107 - PubMed
  141. Pedroso JL, Pinto WB, Souza PV, et al. Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis. Epilepsy Behav. 2012;24(3):380-381. doi:10.1016/j.yebeh.2012.04.121 - PubMed
  142. Zacherl M, Sourij H, Beham A, Emberger W, Leithner A, Windhager W. Cerebrotendinous xanthomatosis. Hereditary lipid storage disease leading to bilateral swelling of Achilles tendon. Orthopade. 2008;37(7):704-708. doi:10.1007/s00132-008-1275-8 - PubMed
  143. Embiruçu EK, Otaduy MC, Taneja AK, Leite CC, Kok F, Lucato LT. MR spectroscopy detects lipid peaks in cerebrotendinous xanthomatosis. AJNR Am J Neuroradiol. 2010;31(7):1347-1349. doi:10.3174/ajnr.A1885 - PubMed
  144. Shaji B, Srikumar B, Ramachandran D. A preventable ataxia: Cerebrotendinous xanthomatosis. Ann Indian Acad Neurol. 2019;22(4):493-496. doi:10.4103/aian.AIAN_126_18 - PubMed
  145. Caroppo P, D'Agata F, Mignarri A, Stromillo ML, Dotti MT, Mongini T. Brain metabolism changes after therapy with chenodeoxycholic acid in a case of cerebrotendinous xanthomatosis. Neurol Sci. 2013;34(9):1693-1696. doi:10.1007/s10072-012-1262-z - PubMed
  146. Fraidakis MJ. Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry. 2013;3(9):e302. doi:10.1038/tp.2013.76 - PubMed
  147. Bonnot O, Fraidakis MJ, Lucanto R, et al. Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic acid. CNS Spectr. 2010;15(4):231-236. doi:10.1017/s1092852900000067 - PubMed
  148. Alcalay R, Wu S, Patel S, Frucht S. Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis. Mov Disord. 2009;24(9):1397-1399. doi:10.1002/mds.22585 - PubMed
  149. Androdias G, Vukusic S, Gignoux L, et al. Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis. J Neurol. 2012;259(2):364-366. doi:10.1007/s00415-011-6167-x - PubMed
  150. Bourkiza R, Joyce S, Patel H, et al. Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1-a case report. Ophthalmic Genet. 2010;31(2):73-76. doi:10.3109/13816810903584963 - PubMed
  151. Razi SM, Gupta AK, Gupta DC, Gutch M, Gupta KK, Usman SI. Cerebrotendinous xanthomatosis (a rare lipid storage disorder): a case report. J Med Case Reports. 2016;10(1):103. doi:10.1186/s13256-016-0882-y - PubMed
  152. Larson A, Weisfeld-Adams JD, Benke TA, Bonnen PE. Cerebrotendinous xanthomatosis presenting with infantile spasms and intellectual disability. JIMD Rep. 2017;35:1-5. doi:10.1007/8904_2016_16 - PubMed
  153. Schotsmans K, De Cauwer H, Baets J, et al. Cerebrotendinous xanthomatosis presenting with asymmetric parkinsonism: a case with I-123-FP-CIT SPECT imaging. Acta Neurol Belg. 2012;112(3):287-289. doi:10.1007/s13760-012-0064-7 - PubMed
  154. Schöls L, Nägele T, Schüle R, Berg D. Cerebrotendinous xanthomatosis. Neurology. 2006;67(11):E20. doi:10.1212/01.wnl.0000247673.08554.0f - PubMed
  155. Kamate M, Chetal V, Hattiholi V. Cerebrotendinous xanthomatosis. Indian J Pediatr. 2010;77(6):697-698. doi:10.1007/s12098-010-0070-9 - PubMed
  156. Vadapalli S. Cerebrotendinous xanthomatosis. Indian J Orthop. 2013;47(2):200-203. doi:10.4103/0019-5413.108918 - PubMed
  157. Muniaswamy M, Rengasamy M, Aravamuthan R, Krishnasamy M. Cerebrotendinous xanthomatosis. Indian Dermatol Online J. 2016;7(4):336-338. doi:10.4103/2229-5178.185484 - PubMed
  158. Mak CM, Lam KS, Tan KC, Ma OC, Tam S. Cerebrotendinous xanthomatosis in a Hong Kong Chinese kinship with a novel splicing site mutation IVS6-1G>T in the sterol 27-hydroxylase gene. Mol Genet Metab. 2004;81(2):144-146. doi:10.1016/j.ymgme.2003.11.005 - PubMed
  159. Rashvand Z, Kahrizi K, Najmabadi H, Najafipour R, Omrani MD. Clinical and genetic characteristics of splicing variant in CYP27A1 in an Iranian family with cerebrotendinous xanthomatosis. Iran Biomed J. 2021;25(2):132-139. doi:10.29252/ibj.25.2.132 - PubMed
  160. Smalley SV, Preiss Y, Suazo J, et al. Novel splice-affecting variants in CYP27A1 gene in two Chilean patients with cerebrotendinous xanthomatosis. Genet Mol Biol. 2015;38(1):30-36. doi:10.1590/S1415-475738120140087 - PubMed
  161. Souza PVS, Bortholin T, Naylor FGM, Pinto WBVR, Oliveira ASB. Teaching neuroimages: early-onset dementia and demyelinating neuropathy disclosing cerebrotendinous xanthomatosis. Neurology. 2017;89(11):e134. doi:10.1212/WNL.0000000000004363 - PubMed
  162. Muhammed K, Nandakumar G, Saritha S. Cerebrotendinous xanthomatosis: need for early diagnosis. Indian J Dermatol Venereol Leprol. 2006;72(5):364-366. doi:10.4103/0378-6323.27754 - PubMed
  163. Gaikwad SB, Garg A, Mishra NK, Gupta V, Srivastava A, Sarkar C. Cerebrotendinous xanthomatosis: neuroimaging findings in two siblings from an Indian family. Neurol India. 2003;51(3):401-403. - PubMed
  164. Clemen CS, Spottke EA, Lütjohann D, et al. Cerebrotendinous xanthomatosis: a treatable ataxia. Neurology. 2005;64(8):1476. doi:10.1212/01.WNL.0000158671.84150.8F - PubMed
  165. Ahmed Ghassem M, Mounach A, Djossou H, et al. Achilles tendon xanthoma and cholestanol revealing cerebrotendinous xanthomatosis: a new case report. Case Rep Rheumatology. 2021;2021:6656584. doi:10.1155/2021/6656584 - PubMed
  166. Dotti MT, Federico A, Garuti R, Calandra S. Cerebrotendinous xanthomatosis with predominant parkinsonian syndrome: further confirmation of the clinical heterogeneity. Mov Disord. 2000;15(5):1017-1019. doi:10.1002/1531-8257(200009)15:5<1017::aid-mds1043>3.0.co;2-f - PubMed
  167. Geraldes R, Santos-Bento M, de Carvalho M. Cerebrotendinous xanthomatosis: no involvement of the autonomic nervous system in a case with severe neuropathy. Neurophysiol Clin. 2007;37(1):47-49. doi:10.1016/j.neucli.2007.01.001 - PubMed
  168. Rossi M, Cesarini M, Gatto EM, Cammarota A, Merello M. A treatable rare cause of progressive ataxia and palatal tremor. Tremor Other Hyperkinet Mov. 2018;8:538. doi:10.7916/D8X07Q2N - PubMed
  169. Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, De Reuck J, Kunnen M. MRI of the brain in cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease). Eur Radiol. 2000;10(4):576-578. doi:10.1007/s003300050964 - PubMed
  170. Fleck JD, Biller J, Mathews VP. Neuroimages: cerebrotendinous xanthomatosis. Neurology. 2000;55(4):601. doi:10.1212/wnl.55.4.601 - PubMed
  171. Siman-Tov T, Meiner V, Gadoth N. Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci. 2006;243(1-2):83-86. doi:10.1016/j.jns.2005.10.019 - PubMed
  172. Lee MH, Hazard S, Carpten JD, et al. Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res. 2001;42(2):159-169. - PubMed
  173. Abdel-Hamid MS, Issa MY, Otaify GA, Zaki MS. A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract. Metab Brain Dis. 2017;32(2):311-315. doi:10.1007/s11011-017-9971-x - PubMed
  174. Appadurai V, DeBarber A, Chiang PW, et al. Apparent underdiagnosis of cerebrotendinous xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab. 2015;116(4):298-304. doi:10.1016/j.ymgme.2015.10.010 - PubMed
  175. Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2014;37(3):421-429. doi:10.1007/s10545-013-9674-3 - PubMed
  176. Gelzo M, Di Taranto MD, Sica C, et al. Age-related changes of cholestanol and lathosterol plasma concentrations: an explorative study. Lipids Health Dis. 2019;18(1):235. doi:10.1186/s12944-019-1176-3 - PubMed
  177. Dayspring TD, Varvel SA, Ghaedi L, Thiselton DL, Bruton J, McConnell JP. Biomarkers of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718 patients. J Clin Lipidol. 2015;9(6):807-816. doi:10.1016/j.jacl.2015.08.003 - PubMed
  178. Morgan AE, Mooney KM, Wilkinson SJ, Pickles NA, Mc Auley MT. Cholesterol metabolism: a review of how ageing disrupts the biological mechanisms responsible for its regulation. Ageing Res Rev. 2016;27:108-124. doi:10.1016/j.arr.2016.03.008 - PubMed
  179. Alphonse PAS, Jones PJH. Revisiting human cholesterol synthesis and absorption: the reciprocity paradigm and its key regulators. Lipids. 2016;51:519-536. doi:10.1007/s11745-015-4096-7 - PubMed
  180. Reeskamp LF, Volta A, Zuurbier L, Defesche JC, Hovingh GK, Grefhorst A. ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia. J Clin Lipidol. 2020;14(2):207-217.e7. doi:10.1016/j.jacl.2020.01.007 - PubMed
  181. Claesen JLA, Koomen E, Schene IF, et al. Misdiagnosis of CTX due to propofol: the interference of total intravenous propofol anaesthesia with bile acid profiling. J Inherit Metab Dis. 2020;43(4):843-851. doi:10.1002/jimd.12219 - PubMed
  182. Freudenberg F, Gothe F, Beigel F, Rust C, Koletzko S. Serum 7-alpha-hydroxy-4-cholesten-3-one as a marker for bile acid loss in children. J Pediatr. 2013;163(5):1367-71.e1. doi:10.1016/j.jpeds.2013.06.083 - PubMed
  183. Björkhem I, Diczfalusy U, Lövgren-Sandblom A, et al. On the formation of 7-ketocholesterol from 7-dehydrocholesterol in patients with CTX and SLO. J Lipid Res. 2014;55(6):1165-1172. doi:10.1194/jlr.P048603 - PubMed
  184. Björkhem I. Five decades with oxysterols. Biochimie. 2013;95(3):448-454. doi:10.1016/j.biochi.2012.02.029 - PubMed
  185. Mast N, Anderson KW, Lin JB, et al. Cytochrome P450 27A1 deficiency and regional differences in brain sterol metabolism cause preferential cholestanol accumulation in the cerebellum. J Biol Chem. 2017;292(12):4913-4924. doi:10.1074/jbc.M116.774760 - PubMed
  186. DeBarber AE, Duell PB. Update on cerebrotendinous xanthomatosis. Curr Opin Lipidol. 2021;32(2):123-131. doi:10.1097/MOL.0000000000000740 - PubMed
  187. Pajares S, Arias A, García-Villoria J, et al. Cholestane-3β,5α,6β-triol: high levels in Niemann-Pick type C, cerebrotendinous xanthomatosis, and lysosomal acid lipase deficiency. J Lipid Res. 2015;56(10):1926-1935. doi:10.1194/jlr.M060343 - PubMed
  188. Lorbek G, Lewinska M, Rozman D. Cytochrome P450s in the synthesis of cholesterol and bile acids-from mouse models to human diseases. FEBS J. 2012;279(9):1516-1533. doi:10.1111/j.1742-4658.2011.08432.x - PubMed
  189. Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci. 2006;27(2):143-149. doi:10.1007/s10072-006-0618-7 - PubMed
  190. Stenson PD, Mort M, Ball EV, et al. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665-677. doi:10.1007/s00439-017-1779-6 - PubMed
  191. https://www.ncbi.nlm.nih.gov/clinvar. - PubMed
  192. Garuti R, Croce MA, Tiozzo R, et al. Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis. J Lipid Res. 1997;38(11):2322-2334. - PubMed
  193. https://gnomad.broadinstitute.org. - PubMed
  194. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66(4):948-983. doi:10.1124/pr.113.008201 - PubMed
  195. Grant SM, DeMorrow S. Bile acid signaling in neurodegenerative and neurological disorders. Int J Mol Sci. 2020;21(17):5982. doi:10.3390/ijms21175982 - PubMed
  196. Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr. 2018;18(2):71-87. doi:10.3727/105221618X15156018385515 - PubMed
  197. Höflinger P, Hauser S, Yutuc E, et al. Metabolic profiling in serum, cerebrospinal fluid, and brain of patients with cerebrotendinous xanthomatosis. J Lipid Res. 2021;62:100078. doi:10.1016/j.jlr.2021.100078 - PubMed
  198. Freedman SF, Brennand C, Chiang J, et al. Prevalence of cerebrotendinous xanthomatosis among patients diagnosed with acquired juvenile-onset idiopathic bilateral cataracts. JAMA Ophthalmol. 2019;137(11):1312-1316. doi:10.1001/jamaophthalmol.2019.3639 - PubMed
  199. Nohara A, Tada H, Ogura M, et al. Homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2021;28:665-678. doi:10.5551/jat.RV17050 - PubMed
  200. Tada H, Nomura A, Ogura M, et al. Diagnosis and management of sitosterolemia 2021. J Atheroscler Thromb. 2021;28:791-801. doi:10.5551/jat.RV17052 - PubMed
  201. Harris J, Cao S, Hile G, Eshaq M. Diffuse xanthomas in a patient with primary biliary cholangitis and lipoprotein X. JAAD Case Rep. 2020;7:30-32. doi:10.1016/j.jdcr.2020.10.029 - PubMed
  202. Brass EP, Stelten BML, Verrips A. Cerebrotendinous xanthomatosis-associated diarrhea and response to chenodeoxycholic acid treatment. JIMD Rep. 2020;56(1):105-111. doi:10.1002/jmd2.12163 - PubMed
  203. Tabei KI, Satoh M, Ogawa JI, et al. Cognitive function and brain atrophy predict non-pharmacological efficacy in dementia: the Mihama-Kiho scan Project2. Front Aging Neurosci. 2018;10:87. doi:10.3389/fnagi.2018.00087 - PubMed
  204. Benedict RH, Carone DA, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging. 2004;14(3):36S-45S. doi:10.1177/1051228404266267 - PubMed
  205. Argyropoulos GPD, van Dun K, Adamaszek M, et al. The cerebellar cognitive affective/Schmahmann syndrome: a task force paper. Cerebellum. 2020;19(1):102-125. doi:10.1007/s12311-019-01068-8 - PubMed
  206. Olivito G, Clausi S, Laghi F, Tedesco AM, Baiocco R, Mastropasqua C. Resting-state functional connectivity changes between dentate nucleus and cortical social brain regions in autism spectrum disorders. Cerebellum. 2017;16(2):283-292. doi:10.1007/s12311-016-0795-8 - PubMed
  207. Stelten BML, Bonnot O, Huidekoper HH, et al. Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41(4):641-646. doi:10.1007/s10545-017-0086-7 - PubMed
  208. Pilo B, de Blas G, Sobrido MJ, et al. Neurophysiological study in cerebrotendinous xanthomatosis. Muscle Nerve. 2011;43(4):531-536. doi:10.1002/mus.21905 - PubMed
  209. Stelten BML, van de Warrenburg BPC, Wevers RA, Verrips A. Movement disorders in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord. 2019;58:12-16. doi:10.1016/j.parkreldis.2018.07.006 - PubMed
  210. Su CS, Chang WN, Huang SH, et al. Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord. 2010;25(4):452-458. doi:10.1002/mds.22979 - PubMed
  211. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol. 1997;17(4):680-687. doi:10.1161/01.atv.17.4.680 - PubMed
  212. Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol. 2000;20(11):2346-2348. doi:10.1161/01.atv.20.11.2346 - PubMed
  213. Federico A, Dotti MT, Loré F, Nuti R. Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci. 1993;115(1):67-70. doi:10.1016/0022-510x(93)90068-a - PubMed
  214. Martini G, Mignarri A, Ruvio M, et al. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int. 2013;92(3):282-286. doi:10.1007/s00223-012-9677-3 - PubMed
  215. Zübarioğlu T, Bilen İP, Kıykım E, et al. Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis. Turk Pediatri Ars. 2019;54(2):113-118. doi:10.14744/TurkPediatriArs.2019.23281 - PubMed
  216. Kollmer J, Sahm F, Hegenbart U, et al. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology. 2017;89(5):475-484. doi:10.1212/WNL.0000000000004178 - PubMed
  217. Guerrera S, Stromillo ML, Mignarri A, et al. Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry. 2010;81(11):1189-1193. doi:10.1136/jnnp.2009.203364 - PubMed
  218. Soffer D, Benharroch D, Berginer V. The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol. 1995;90(2):213-220. doi:10.1007/BF00294324 - PubMed
  219. Pop PH, Joosten E, van Spreeken A, et al. Neuroaxonal pathology of central and peripheral nervous systems in cerebrotendinous xanthomatosis (CTX). Acta Neuropathol. 1984;64(3):259-264. doi:10.1007/BF00688117 - PubMed
  220. Stelten BML, van der Knaap MS, Wevers RA, Verrips A. Cerebellar disease mimicking cerebrotendinous xanthomatosis: Langerhans cell histiocytosis. Pediatr Neurol. 2017;73:98-100. doi:10.1016/j.pediatrneurol.2017.04.007 - PubMed
  221. Mandia D, Chaussenot A, Besson G, et al. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol. 2019;266(8):2043-2050. doi:10.1007/s00415-019-09377-y - PubMed
  222. Amador MDM, Masingue M, Debs R, et al. Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes. J Inherit Metab Dis. 2018;41(5):799-807. doi:10.1007/s10545-018-0162-7 - PubMed
  223. Verrips A, Dotti MT, Mignarri A, Stelten BML, Verma S, Federico A. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies. Neurol Sci. 2020;41(4):943-949. doi:10.1007/s10072-019-04169-8 - PubMed

Publication Types